Felice Su, M.D., Pediatric Critical Care Fellow, Department of Anesthesia and Critical Care, Children’s Hospital of Philadelphia. Felice Su received her B.A. in Science at Northwestern University in Evanston, IL (1993-1997), and went to medical school at Feinberg School of Medicine at Northwestern University in Chicago, IL (1996-2000). She completed her residency training in pediatric medicine at the University of Texas Southwestern, Children’s Medical Center in Dallas, TX (2001-2003). Dr. Su recently completed a fellowship in pediatric critical care at The Children's Hospital of Philadelphia. Her research interests and focus are in clinical pharmacology with an emphasis on drug development in critically ill pediatric patients. Her current research project involves defining the pharmacokinetic (PK) and pharmacodynamic (PD) profile of dexmedetomidine in infants post-operative from open heart surgery. During the ITMAT fellowship, she will extend the study of dexmedetomidine to the neonatal population and use the combined PK profiles to construct population PK models that will allow for improvement in future dexmedetomidine clinical trial design.
Kenneth H. Yu, M.D., Instructor, Division of Hematology/Oncology, University of Pennsylvania Kenneth Yu received his B.A. in Biology at Harvard University in (1991-95), then went on to medical school at Johns Hopkins University (1995-99). He completed his residency training in Internal Medicine at the Hospital of the University of Pennsylvania (1999-02). Pursuing a life-long interest in cancer, he recently completed a fellowship in Hematology/Oncology at Penn. During this time, Dr. Yu developed an interest in gastrointestinal malignancies, and pancreatic cancer in particular. In 2003, he joined the laboratory of Ian Blair in the Department of Pharmacology, and began investigating tumor markers for the diagnosis of pancreatic cancer using proteomic techniques. Tumor markers hold the promise of earlier diagnosis of disease and insight into the mechanisms underlying disease progression. Using 2-D gel electrophoresis, multi-dimensional liquid chromatography, novel labeling techniques, high performance mass spectrometers and sophisticated bioinformatics, we have made significant progress in the development of potential biomarkers for pancreatic cancer. Tumor markers provide an ideal opportunity to translate basic research findings into the clinical setting. Dr. Yu plans on continuing this work as part of the Institute for Translational Medicine and Therapeutics fellowship. His work has resulted in two manuscripts recently published in the Journal of Proteome Research. His research advances with the active collaboration of Anil Rustgi, Department of Gastroenterology, and David Tuveson, Division of Hematology/Oncology.